Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq
@ASCO
🚨 BREAKING:
CMS just confirmed the Medicare GLP-1 Bridge program is still a go for July 1, 2026.
Eligible Medicare patients will be able to access certain GLP-1 medications for $50/month.
Huge for $LLY and $NVO
12.4% of US adults are on a GLP-1s.
It was 5.8% in Feb 2024.
It doubled in 18 months. The global anti-obesity market is projected to grow from $19.6B today to $104.9B in 2035.
This is the fastest mainstream drug adoption of our lifetime.
🚨 BREAKING: AMAZON ONE MEDICAL LAUNCHES GLP-1 PROGRAM
- Starting at $25/mo with insurance
- $149/mo cash-pay for oral GLP-1s (Wegovy Pill and Founday)
- $299/mo cash-pay for injectables (Wegovy Pen, Zepbound, KwikPen)
$NVO $LLY $HIMS
🚨 ELI LILLY IS PUSHING HARD TO GET RETATRUTIDE CLASSIFIED AS A "BIOLOGIC"
If successful, would extend market exclusivity beyond normal drug limits AND compounding pharmacies would be prohibited from making it
$LLY $NVO $HIMS
It’s almost like this whole brand / generic thing is a great structure to incentive r&d while ensuring broad affordability on a reasonable timeline.
Plenty of doctors promote bad information online.
Certainty does not equal expertise.
I learned long ago that it's better to provide good information that try to battle bad information, so I humbly offer this level 1 evidence on the safety and efficacy of colonoscopy:
1. Colonoscopy is safe, and the risk of perforation during screening is 3.1 per 10,000, or 0.031%. If you are that unlucky 1 in 3,226 people, the risk of it killing you is less than 5%
Source: https://t.co/XREVXOYGhf
2. Colonoscopy reduces your chance of getting colorectal cancer, and it reduces your chance of dying from colorectal cancer. In fact, there's a 68% reduction in CRC mortality with colonoscopy.
Source: https://t.co/9rqtHDCJUW
I try my best to ignore physicians who use twitter to promote pseudoscience and generate traffic to their websites, but it's Colorectal Cancer Awareness Month, so I feel obligated to share my thoughts.
Thinking about prescribing compounded medications? Here are three questions to ask before choosing a pharmacy partner.
1. Are they accredited? Look for PCAB or NABP accreditation—the recognized standards for compounding quality and safety.
2. Do they comply with USP standards? USP chapters 795, 797, and 800 govern non-sterile, sterile, and hazardous drug compounding, respectively.
3. Can you see pricing before you prescribe? Transparent cash pricing protects both your patients and your practice from unexpected costs.
eNavvi’s platform is designed to help clinicians answer all three questions before a single prescription is sent.
Informed prescribing starts with the right tools. Explore https://t.co/P2BoHYt2Ak
NEW: AI just became legally authorized to practice medicine in the US.
Actually prescribing with no doctor in the loop.
Doctronic launched a pilot where its AI renews prescriptions for chronic conditions, reviews history, asks questions, and sends the Rx to the pharmacy.
This might be the most badass brief report I’ve read in a long time.
In @NEJM
A team just published what feels like a glimpse straight into the future of cellular therapeutics: successful survival and function of transplanted allogeneic, CRISPR-edited beta cells with zero immunosuppression — in a real human with long-standing type 1 diabetes.
No anti-rejection meds.
No immune flare.
Glucose-responsive insulin secretion documented weeks after implantation.
A clean safety profile.
This is the kind of translational science that makes you think about how close we might be to rewriting what’s possible in autoimmune and metabolic disease.
Medicine is moving fast. This is one of those papers that makes you feel it.
🍂 Don’t let high drug prices get you down.
With eNavvi, prescriptions that usually cost $80 can drop to just $20! 💊💰
Compare cash prices instantly and prescribe smarter → https://t.co/UcM6vuHfoD
#eNavvi#FallSavings#DigitalHealth#AffordableCare
Save Big on Rivaroxaban 💊
Through eNavvi, physicians can now prescribe rivaroxaban directly to @CostPlusDrugs — giving patients transparent, upfront pricing.
✨ The deal:
Rivaroxaban as low as $20.73
Compared to retail prices over $200+
No surprises. Just real savings your patients can count on.
Prescribe with confidence, save patients money
☕️ Late night? Patients don’t wait for business hours.
With eNavvi, your free digital prescription pad, you can prescribe anytime, anywhere—right from your phone.
No desk. No hassle. Just care.
#PhysicianLife#DigitalHealth